Meral Beksaç

Allogeneic Hematopoietic Cell Transplantation for Relapsed/ Refractory Hodgkin Lymphoma: A Multicenter Real-World Experience

Derya Koyun, Uğur Şahin, Güldane Cengiz Seval, Deniz Gören et autres

tr (code pays fourni par la source)

Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age

Peter M. Voorhees, Meletios Α. Dimopoulos, Yaël C. Cohen, Fredrik Schjesvold et autres

us, gr, il, no, br, ca, gb, au, jp, nl, tr, es, hu, ar, be, cz, dk, it, se, de (code pays fourni par la source)

Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial

Meletios Α. Dimopoulos, Meral Beksaç, Sosana Delimpasi, Vladimir Vorobyev et autres

gr, tr, cz, ru, au, pl, kr, it, jp, gb, us, es, ca (code pays fourni par la source)

Characterization of Infections in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf)–Based Regimens From the DREAMM-7 and DREAMM-8 Trials

Paweł Robak, Vânia Hungria, Luděk Pour, Kihyun Kım et autres

Updated Results From the Phase 3 DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Meletios Α. Dimopoulos, Meral Beksaç, Luděk Pour, Sosana Delimpasi et autres

POSTER: MM-771 Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Patients With Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of Transplant-ineligible (TIE) Patients in the Phase 3 CEPHEUS Study

Saad Z. Usmani, Sonja Zweegman, Vânia Hungria, Nizar J. Bahlis et autres

MM-1485: DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Abnormalities

Suzanne Trudel, Meral Beksaç, Luděk Pour, Sosana Delimpasi et autres

ca, tr, cz, gr, au, ru, it, jp, pl, us, ie, es (code pays fourni par la source)

MM-1039: Characterization of Infections in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin-Based Regimens From the Randomized, Phase 3 DREAMM-7 and DREAMM-8 Trials

Paweł Robak, Vânia Hungria, Luděk Pour, Kihyun Kım et autres

pl, br, cz, kr, ru, au, es, gr, gb, us, tr (code pays fourni par la source)

MM-771: Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Patients With Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of Transplant-ineligible (TIE) Patients in the Phase 3 CEPHEUS Study

Saad Z. Usmani, Sonja Zweegman, Vânia Hungria, Nizar J. Bahlis et autres

us, nl, br, ca, cz, es, gb, il, jp, fr, pl, tr (code pays fourni par la source)

POSTER: MM-1485 DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Abnormalities

Suzanne Trudel, Meral Beksaç, Luděk Pour, Sosana Delimpasi et autres

ca, tr, cz, gr, au, ru, it, jp, pl, us, ie, es (code pays fourni par la source)

Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions

Paul G. Richardson, Elisabeth K. O’Donnell, Peter O’Gorman, Lisa Leypoldt et autres

us, au, ie, de, it, fr, ca, kr, gr, jp, tr (code pays fourni par la source)

Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network

Niels W.C.J. van de Donk, Philippe Moreau, Jesús F. San Miguel, María‐Victoria Mateos et autres

nl, fr, es, gr, by, it, de, be, tr, au, no, ch, gb, cz, at (code pays fourni par la source)